Abstract: The present disclosure provides modified neuroactive steroids. The modified neuroactive steroids may comprise, consist of or consist essentially of a therapeutic agent and/or a modifying moiety. The modified neuroactive steroid can have modified characteristics as compared to native neuroactive steroids that do not include a modifying moiety and/or therapeutic agent. The modified neuroactive steroid may be, for example, modified pregnenolone, pregnenolone metabolites, allopregnanolone, and/or allopregnanolone metabolites. The modified neuroactive steroids can be used to treat, prevent and/or ameliorating a phenotypic state of interest in a subject.

Abstract: The invention relates to compounds of formula (I) wherein R1, R2, Y1, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.

Abstract: A method of preparing and separating biopolymers and biopolymer fractions is useful for wastewater treatment applications from sewage sludge. The method comprising the steps of disrupting the bacterial cell walls of bacteria present in the sewage sludge by at least 75% to release the intracellular contents of the bacterial cells and separating the biopolymers from any contaminants present.

Abstract: Disclosed are amino acid mimetics that possess antibiotic properties in prokaryotic cells. These mimetics are coupled to one or more optionally substituted amino acids provided that at least one of the amino acids is an optionally substituted amino acid selected from the group consisting of phenylglycine, tryptophan, phenylalanine, histidine, and tyrosine.

Abstract: The disclosed peptidomimetic macrocycles modulate the activity of MCL-1. Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which MCL-1 is over-expressed, such as cancer. In particular, MCL-1-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by MCL-1 over-expression or hyper-activation.

Abstract: The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralising a tooth lesion such as a subsurface caries lesion.

Abstract: Replicon virus-like particles can be used as flavivirus vaccines.

Abstract: Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.

Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.

Abstract: Methods and compounds for conferring site-specific or local immune privilege.

Abstract: The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.

Abstract: The present invention relates to novel peptides derived from Prorelaxin H1 (RLN1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

Abstract: The present invention concerns the use of an inhibitor of an interaction between type IV pilus-associated protein and CD147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection. The invention also relates to a method for the prevention and/or treatment of meningococcal bacteraemia and/or infection, and to a method for screening inhibitors of the interaction between type IV pilus-associated protein and CD147.

Abstract: The present invention relates to novel peptides derived from Structural maintenance of chromosomes protein 1 B (SMC1 B), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Provided herein are materials and methods for delivering immunoglobulins (e.g. therapeutic immunoglobulins) across the blood-brain barrier.

Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.

Abstract: The methods and uses described herein relate to the treatment of age-related conditions, e.g. by administering an agent that inhibits the interaction of GDF11 and follistatin. In some embodiments, the agent can bind to an epitope of GDF11 as described herein.

Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.

Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

Abstract: The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.

Abstract: Methods and compositions for regulating fatty acid uptake and/or decreasing gastric motility in an animal are provided.

Abstract: The invention provides methods for the treatment of seizures and epilepsy using FGF21 receptor activators.

Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Abstract: A process of utilizing a light generating microcapsule to cure a photo-curable material includes dispersing a microcapsule in an interface material that includes a photo-initiator and a photo-curable material. The process also includes applying a stimulus to the microcapsule to trigger a chemiluminescent reaction within the microcapsule. The chemiluminescent reaction generating a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photo-initiator. The photon generated within the microcapsule exits the microcapsule into the interface material to trigger the photo-initiator to initiate or catalyze curing of the photo-curable material.

Abstract: Disclosed herein is a composition comprising a co-continuous interpenetrating network of an organic polymer and a electroactive moiety; where the organic polymer is operative to depolymerize at a temperature of 50 to 500° C. and to repolymerize on a surface in the presence of the electroactive moiety; and where the electroactive moiety is an organic semiconductor that does not react with a repolymerized polymer. Disclosed herein too is a method comprising co-evaporating a polymeric precursor and an electroactive moiety onto a substrate; condensing the polymeric precursor and an electroactive moiety on the substrate; and polymerizing the polymeric precursor to form a co-continuous interpenetrating network of an organic polymer and an electroactive moiety; where the electroactive moiety is defined as a chemical functional group which is capable of transporting an electrical charge.

Abstract: This invention relates to the preparation and utility of proliferous polymer compositions comprising repeating units derived from (a) a monomer comprising at least one functionalized or unfunctionalized acryloyl moiety and at least one lactam moiety, (b) an optional monomer comprising at least one double bond, and (c) a at least one cross-linker.

Abstract: The present disclosure relates a method of preparing a rubbery polymer, a rubbery polymer, and a graft copolymer and thermoplastic resin composition including the rubbery polymer. In accordance with the present disclosure, a rubbery polymer, in which a large-diameter rubbery polymer and a small-diameter rubbery polymer are formed in a desired ratio by controlling the contents, addition time points, and types of a crosslinking agent, an emulsifier, and a molecular weight regulator when a conjugated diene monomer, the crosslinking agent, the molecular weight regulator, and the emulsifier are polymerized, and a graft copolymer and thermoplastic resin composition having excellent surface gloss and mechanical properties are provided.

Abstract: The present invention provides a water-soluble silicone macromer. The water-soluble silicone macromer has a general formula: E-(M1)x-(M2)y, wherein M1 is a repeating unit which is derived from a silicone containing monomer, M2 is a repeating unit which is derived from a first hydrophilic monomer, and E is an ethylenically unsaturated group. The amount of M1 is in a range of 30-60 wt % based on the total weight of the water-soluble silicone macromer, and the amount of M2 is in a range of 40-70 wt % based on the total weight of the water-soluble silicone macromer. A silicone hydrogel composition containing the water-soluble silicone macromer and a silicone hydrogel lens made of the silicone hydrogel composition are also provided herein.

Abstract: Condensation polymers are prepared by agitating a mixture comprising glyoxal, a monomer comprising two or three primary aromatic amine groups, an organic solvent, and water at a temperature between 20° C. and 100° C. The resulting solution can be applied to a surface of a substrate, forming an initial film. Curing the initial film layer using two or more heating steps, wherein one of the heat steps is performed at a temperature of 150° C. to 250° C., produces a cured film layer. Depending on the relative amounts of glyoxal and monomer used, the film layer can contain predominantly high Tg imine-containing units or predominantly lower Tg aminal-containing units. All film layers were highly resistant to the solvent used to prepare the polymer. The Tg of the polymer can be about 190° C. to greater than 300° C.

Abstract: Disclosed are high strength polyurethane foam compositions and methods of making them. In one aspect, the inventive polyurethane foams include strength enhancing additives comprising one or more polycarbonate polyols derived from the copolymerization of CO2 and one or more epoxides. In one aspect, the inventive methods include the step of substituting a portion of the polyether polyol in the B-side of a foam formulation with one or more polycarbonate polyols derived from the copolymerization of CO2 and one or more epoxides.

Abstract: Aspects described herein generally describe epoxy resins and methods of epoxy resin formation. In some embodiments, a resin includes the reaction product of one or more polythiols, one or more polyepoxides, one or more fillers and one or more amine catalysts. Polythiols have between two and about ten thiol moieties. Polyepoxides have between two and about ten epoxy moieties. One or more amine catalysts of the formula NR1R2R3, wherein each of R1, R2, and R3 is independently linear or branched C1-20 alkyl or two or more of R1, R2, and R3 combine to form cycloalkyl. The resin has a compressive strength of at least 14 ksi at 2% offset at 70° F. and at least 8 ksi at 2% offset at 190° F.

Abstract: There is provided an epoxy resin composition containing an epoxy compound, which has a low viscosity and a low dielectric constant, and when added to a general-purpose epoxy resin composition, can lower a viscosity of the composition and can sufficiently lower a dielectric constant of an epoxy resin cured product obtained from the composition. An epoxy resin composition comprising: (a) an epoxy component containing at least an epoxy compound of formula [1]; and (b) a curing agent: wherein R1 to R3 each independently are a hydrogen atom or methyl group, and L1 to L3 each independently are pentamethylene group, hexamethylene group or heptamethylene group.

Abstract: A method for producing a polyester includes: a) subjecting a mixture which includes a major amount of a first monomer and a minor amount of a second monomer to a pre-polymerization reaction at a first temperature for a period of reaction time such that a prepolymer is formed while a glycol compound is continuously removed by distillation; and b) subjecting the prepolymer to a polymerization reaction at a second temperature higher than the first temperature to obtain the polyester.

Abstract: A customizable polyamide polymer, in particular Nylon 66, Nylon 6, and copolyamides, having a high molecular weight, excellent color, and low gel content is disclosed. In particular, disclosed is a polymer having a relative viscosity greater than 50 as measured in a 90% strength formic acid solution; consistent viscosity with a standard deviation of less than 1; a gel content no greater than 50 ppm as measured by insolubles larger than 10 micron; an optical defect content of less than 2,000 parts per million (ppm) as measured by optical control system (OCS). The polymer can be made into monofilaments or a multifilament yarn. Also disclosed is a process of producing the polymer using in-line vacuum finishing technology in the absence of steam or other gases in the second, or post condensation, step of the polymer process.

Abstract: Provided are a method of producing a polyarylene sulfide (PAS) by a polymerization reaction of a sulfur source and a dihalo aromatic compound in an organic amide solvent, in which the PAS having a high degree of polymerization can be obtained at a high yield and the generation of a byproduct that imposes a large burden of a waste treatment can be effectively reduced; and a PAS having a high degree of polymerization. The method of producing a PAS includes a preparation step of preparing a charged mixture containing an organic amide solvent, a sulfur source, water, and a dihalo aromatic compound; a first-stage polymerization step of performing a polymerization reaction on the charged mixture at a temperature of from 170 to 280° C. to produce a prepolymer having a conversion ratio of the dihalo aromatic compound of 50% or greater; and a second-stage polymerization step of continuing the polymerization reaction in a phase-separated state at a temperature of from 245 to 290° C.

Abstract: A polymerizable composition for an optical material includes an episulfide compound (A); an organic coloring matter (B); an UV absorber (C); and a polymerization catalyst (D), wherein the organic coloring matter (B) has a main absorption peak (P) between 565 nm and 605 nm in a visible light absorption spectrum, an absorption coefficient (ml/g·cm) of a peak apex (Pmax) exhibiting a maximum absorption coefficient of (P) is equal to or greater than 0.5×105, a peak width in an absorbance of ¼ of an absorbance of (Pmax) of (P) is equal to or less than 50 nm, a peak width in an absorbance of ½ of the absorbance of (Pmax) of (P) is equal to or less than 30 nm, and a peak width in an absorbance of ? of the absorbance of (Pmax) of (P) is in a range of equal to or less than 20 nm.

Abstract: The present invention provides polymer compositions of one or more phosphorus acid group containing, polymers of six-membered cyclic methacrylic acid imide comprising a backbone polymer having one or more one methacrylic acid in polymerized form or its salt, quaternary ammonium group, ester side chain group or amide side chain group, wherein the backbone polymers comprise from 60 to 100 wt. %, based on the total weight of monomers used to make the backbone polymer, of total methacrylic acid polymerized units, regardless of their form, and wherein a total of from 7.5 to 95 wt. %, or, preferably, less than 70 wt. % of the methacrylic acid polymerized units comprise methacrylic anhydride groups or six-membered cyclic methacrylic imide groups. The polymer can be readily tailored to boost modulus and modify surface energies when added to polymers like polyolefins, and to make them compatible with other polymers, like polyamide.

Abstract: Disclosed are latexes, suspensions, and colloids having a cationic antimicrobial compound complexed with an anionic surfactant. The surfactant may have greater affinity for the antimicrobial compound than other anionic surfactants and other anions in the latex, suspension, or colloid that contribute to disperse phase stability to prevent disrupting the dispersions. Dispersions containing the antimicrobial compound may therefore have a shelf life comparable to dispersions that are otherwise identical but lack the cationic antimicrobial compound and its complexed anionic surfactant. Coatings made with the complexes can exhibit essentially undiminished antimicrobial activity.

Abstract: A binder resin composition for a preform has a Tg of 50° C. to 100° C., a complex viscoelastic coefficient G* determined by dynamic viscoelasticity measurement of 10 kPa to 500 kPa at Tg+30° C., and “G* at Tg+30° C./G* at Tg+80° C.” of 10 to 300, wherein the viscosity monotonically decreases as temperature of the binder resin composition for a preform rises to 200° C. The binder resin composition is excellent in storage stability at ordinary temperatures and adhesiveness between preform layers at low temperatures, and is capable of exhibiting stable adhesiveness even when the temperature during preform molding is uneven. A reinforcing fiber base material, a preform, and a fiber reinforced composite material include the binder resin composition.

Abstract: The present invention relates to a method for applying, to an inorganic surface, a self-adhesive PVC composition which comprises a composition (C) comprising: an optionally protected aminosilane; and at least one compound selected from a titanium complex, a zirconium complex and an optionally protected isocyanate compound; said method comprising a step of activating said surface, selected from heat treatment, a shot-peening step, a plasma treatment step, cleaning With solvent and a step of silica application.

Abstract: The present disclosure is directed to films. The films can include polyamic acid (PAA). Methods of making and using the film for food product coverings is also included.

Abstract: The method for producing a transparent conductive substrate includes forming metal meshes on a flexible non-conductive substrate with high transmittance. It's unnecessary to use palladium as a catalyst in this method. The metal meshes are in the form of nano/micro wires and the conductive substrate has high transmittance of 80%-90% at visible light wavelengths of 390-750 nm.

Abstract: A method of producing a modified fibrous wollastonite is provided. The method includes hydrothermally treating a fibrous wollastonite.

Abstract: A gasket material comprising polytetrafluoroethylene (PTFE) and high purity filler is described. The gasket material can include from 50 to 60 wt % PTFE and from 40 to 50 wt % high purity filler. The high purity filler can be high purity quartz, such as wherein the filler comprises greater than or equal to 99.996% quartz as the primary filler material. The PTFE can be full density PTFE. The gasket material can be provided in the form of a sheet, and can exhibit biaxial material properties. A core metal sheet can be encapsulated within the gasket material sheet, such as a corrugated metal sheet. Annular gasket seals can be formed from the gasket material sheet.

Abstract: An effective dried attractive toxic bait station that acts as a lure and kill device for Ae. aegypti and other mosquitoes. The bait station is a simulated refuge at least part of which is coated with a dried mixture of poison and sugar forming a dried toxic sugar-containing bait. The simulated refuge attracts Ae. aegypti and other mosquitoes to bait station and encourages them to land on the coated portion. Once a mosquito has landed, it detects the sugar in the dried mixture of sugar and poison and ingests some of it. Once ingested, the dried mixture of poison and sugar will eventually kill the mosquito.

Abstract: The invention provides plasticisers for polymeric compositions, particularly advantageous for PVC compositions, exhibiting a good heat and mechanical stability, as well as a low toxicity. The plasticisers are tri-esters of 1,2,4-benzenetriol and can be obtained in a low-cost process.